Compare F5 Inc (FFIV) vs Gilead Sciences, Inc. (GILD) Price & Performance

F5 (FFIV) trades at $466.65, down 0.67% on the day, as the stock consolidates near recent highs following strong year-to-date performance. The company continues to demonstrate robust fundamentals with revenue growth accelerating to $3.09 billion in 2025 and net income reaching $692 million, representing a 22.4% margin. Recent analyst recognition as a leader in WAAP platforms and AI security positions F5 well in the growing cybersecurity market. Technical indicators show the stock trading near resistance at $468 with bullish moving averages but overbought RSI readings suggesting potential near-term consolidation.

F5 presents a compelling growth story with consistent earnings beats and expanding profitability, though current valuation multiples appear elevated. The main investment opportunity lies in the company's leadership in application security and AI-driven solutions, while risks include competitive pressures and execution challenges in maintaining growth momentum. Analyst consensus remains cautiously optimistic with a $416.60 price target, indicating potential downside from current levels despite the positive business trajectory.

Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.

Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.